The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate;Relevancia clinica de las determinaciones seriadas de concentraciones sericas de carbamacepina y valproato sodico

Revista de Neurologia

Volumn 28, Issue 11, 1999, Pages 1043-1047

  Hernandez Fustes O J ^a  

^a HOSPITAL UNIVERSITÁRIO CAJURU   (Brazil)

Author keywords

Carbamazepine; Clinical pharmacology; Serum concentrations; Valproate

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; PHENYTOIN; PRIMIDONE; VALPROIC ACID; ANTICONVULSIVE AGENT;

AMBULATORY MONITORING; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; BLOOD; DRUG COMBINATION;

ANTICONVULSANTS; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; VALPROIC ACID;

EID: 0033144480     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2811.98074     Document Type: Article

References (32)

1. Meinardi H, Hanke NFJ, Beveren JV. Sodium di-N-propylacetate: estimation of effective serum levels. Pharmacol Week 1974; 109: 45-7.
2. Burr W, Froescher W, Hoffmann F, Stefan H. Lack of significant correlation between circadian profiles of valproic acid serum levels and epileptiform electroencephalographic activity. Ther Drug Monit 1984; 6: 179-81.
3. Schobben F, van der Kleijn E. Determination of sodium di-N-propyl-acetate in plasma by gas-liquid chromatography. Pharmacol Week 1974; 109: 30-3.
4. Vajda FJE, Drummer OH, Morris PM, McNeil JJ, Bladin PJ. Gas Chromatographic measurement of plasma levels of sodium valproate: tentative therapeutic range of a new anticonvulsant in the treatment of refractory epileptics. Clin Exp Pharmacol Physiol 1978; 5: 67-73.
5. Gram L, Flachs H, Wurtz-Jorgensen A, Parmas J, Andersen B. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979: 20; 303-12.
6. Wulff K, Flachs H, Wurtz-Jorgensen A, Gram L. Clinical pharmacological aspects of valproate sodium. Epilepsia 1977; 18: 149-57.
7. Ramsay RE, Wilder J, Berger JR, Bruni J. A double blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983; 33: 904-10.
8. Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. Br Med J 1978; 1: 474-6.
9. Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelbue J. A double blind study of carbamazepine and diphenylhydantoin in temporal lobe epilepsy. Acta Neurol Scand 1975; 60: 39-42.
10. Strandjord RE, Johannessen SI. Single drug therapy with carbamazepine in patients with epilepsy: serum and clinical effect. Epilepsia 1980; 21: 655-62.
11. Hoppener RJ, Kuyer A, Meijer JWA, Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effectism patients. Epilepsia 1980: 21: 341-50.
12. Reunane M, Luoma P, Myllyla VV, Hokkanen E. Low serum valproic acid concentrations in epileptic on combination therapy. Curr Ther Res 1990; 9: 456-62.
13. Eadie MJ, Hooper WD. Intermittent carbamazepine intoxication possibly related to altered absorption characteristics of the drug. Med J Aust 1987; 146: 313-6.
14. Johannessen SI, Gerna M, Bakke J, Strandjord RE, Morselli PL. CSF concentrations and serum protein binding of carbamazepine and carbamazepine 10,11 epoxide in epileptic patients. Br J Clin Pharmacol 1976; 3: 575-82.
15. Larkin JG, McLellan A, Munday A, Sutherlan M, Butler E, Brodie MJ. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. Br J Clin Pharmacol 1989; 27: 313-22.
16. Macphee GJA, Brodie MJ. Carbamazepine substitution in severe partial epilepsy: implication in autoinduction of metabolism. Postgrad Med J 1985; 61: 779-83.
17. Paxton JW, Aman MG, Werry JS. Fluctuations in salivary carbamazepine and carbamazepine 10, 11 epoxide concentrations during the day in epileptic children. Epilepsia 1983; 24: 716-24.
18. Riva R, Albani F, Ambrosetto G, Contin M, Cortelli P, Perucca E, et al. Diurnal fluctuations in free and total steady state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984; 25: 476-81.
19. Eichelbaum M, Ekbom K, Bertilsson L, Ringenberger CA, Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after and multiple doses. Eur J Clin Pharmacol 1975; 8: 337-41.
20. Eichelbaum M, Kothe KW, Hoffmann F, von Unruh GE. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 1979; 26: 366-71.
21. Rapeport WG, McInnes GT, Thompson GG, Forrest G, Park BK, Brodie MJ. Hepatic enzyme induction and leucocyte delta aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol 1983; 16: 133-7.
22. Rawlins MD, Collste P, Bertilsson L, Palmer L. Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol 1975; 8: 91-6.
23. Chose K, Fry DE, Christfides JA. Effect of dosage frequency of carbamazepine on drug serum levels in epileptic in patients. Eur J Clin Pharmacol 1983; 24: 375-81.
24. Tomson T. Intradoses fluctuations in plasma carbamazepine concentrations determine side effects. Arch Neurol 1984; 41: 830-4.
25. Dooley JM, Camfield PR, Camfield CS, Gordon KE, Fraser AD. The use of antiepileptic drug levels in children: a survey of Canadian pediatric neurologists. Can J Neurol Sci 1993; 20: 217-21.
26. Levy RH, Cenraud B, Loiseau P, Akbaraly R, Brachet-Liermain A, Guyot M, et al. Meal-dependent absorption of enteric-coated sodium valproate. Epilepsia 1980; 21: 273-80.
27. Turnbull D, Rawlins MD, Weighaman D, Chadwick D. Plasma concentrations of sodium valproate: their clinical value. Ann Neurol 1983; 14: 38-42.
28. Pynonnen S. Pharmacokinetics of carbamazepine in man: a review. Ther Drug Monit 1979; 1: 409-31.
29. Macphee GJA, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 1987; 28: 286-94.
30. Brodie MJ, Hallwarth MJ. Therapeutic monitoring of carbamazepine. Hosp Update 1987; 57-63.
31. Stefan H, Schäfer H, Kuhnen C, Schneider S. Clinical monitoring during carbamazepine slow-release once-daily monotherapy. Epilepsia 1988: 29: 571-7.
32. Eichelbaum M, Kothe KW, Hoffmann F, von Unruh GE. Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment. Eur J Clin Pharmacol 1982; 23: 241-4.